Michał Niedźwiedź

Dr. Michał Niedźwiedź

Department of Dermatology, Paediatric Dermatology and Oncology, Medical University of Lodz, Łódź, Łódzkie, Poland
+5
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Michał NiedźwiedźMichał Niedźwiedź
Michał Niedźwiedź
MSMalgorzata Skibinska
Malgorzata Skibinska
MCMagdalena Ciazynska
Magdalena Ciazynska
MNMarcin Noweta
Marcin Noweta
ACAgnieszka Czerwińska
Agnieszka Czerwińska
ALAleksandra Lesiak
Aleksandra Lesiak
Psoriasis is a multifactorial, chronic, and inflammatory disease that severely impacts patients’ quality of life. The disease is caused by genetic irregularities affected by epigenetic and environmental factors. Some of these factors may include seasonal changes, such as solar radiation, air pollution, and humidity, and changes in circadian rhythm, especially in the temporal and polar zones. Thus, some psoriasis patients report seasonal variability of symptoms. Through a comprehensive review, we aim to delve deeper into the intricate interplay between seasonality, environmental factors, and the genetic and epigenetic landscape of psoriasis. By elucidating these complex relationships, we strive to provide insights that may inform targeted interventions and personalized management strategies for individuals living with psoriasis.

Verified
Journal Article
Open access
PDF file
KWKarina Wierzbowska-Drabik
Karina Wierzbowska-Drabik
Aleksandra LesiakAleksandra Lesiak
Aleksandra Lesiak
MSMalgorzata Skibinska
Malgorzata Skibinska
Michał NiedźwiedźMichał Niedźwiedź
Michał Niedźwiedź
Jaroslaw Damian KasprzakJaroslaw Damian Kasprzak
Jaroslaw Damian Kasprzak
JNJoanna Narbutt
Joanna Narbutt
It is known that both psoriasis (PSO) limited to the skin and psoriatic arthritis (PSA) increase the risk of cardiovascular complications and atherosclerosis progression by inducing systemic inflammatory response. In recent decades, the introduction of biological medications directed initially against TNF-α and, later, different targets in the inflammatory cascade brought a significant breakthrough in the efficacy of PSO/PSA treatment. In this review, we present and discuss the most recent findings related to the interplay between the genetics and immunology mechanisms involved in PSO and PSA, atherosclerosis and the development of cardiac dysfunction, as well as the current PSO/PSA treatment in view of cardiovascular safety and prognosis.

1 February 2023 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
JNJoanna Narbutt
Joanna Narbutt
Michał NiedźwiedźMichał Niedźwiedź
Michał Niedźwiedź
ALAleksandra Lesiak
Aleksandra Lesiak
JCJustyna Ceryn
Justyna Ceryn
MSMałgorzata Skibińska
Małgorzata Skibińska
Psoriasis (PsO) is a chronic, systemic, immune-mediated inflammatory skin disease affecting 1% to 5% population worldwide. In one-third of patients, the first symptoms of PsO manifest in childhood, with a mean age of nine years. Psoriasis in children under 16 years of age constitutes 4% of dermatological problems in this age group. Chronic inflammation of the skin observed in PsO is associated with a development of potentially serious comorbidities, including psoriatic arthritis, hypertension, metabolic syndrome, cardiovascular diseases, inflammatory bowel disease, depression and anxiety. It is reported that among children with psoriasis between 5 and 16 years of age health-related quality of life is reduced by 30.5%. Early diagnosis and effective treatment are crucial in pediatric psoriatic patients to avoid future complications and stigmatization. Treatment for psoriasis consists of a range of topical medications, phototherapy and non-biologic and biologic systemic therapies. Approved biologics for PsO in pediatric patients include etanercept, adalimumab, ustekinumab, ixekizumab and secukinumab. Secukinumab, a recombinant, fully human monoclonal antibody targeting IL-17A, was approved by the EMA (2020) and FDA (2021) in pediatric patients above 6 years of age for the treatment of moderate to severe plaque psoriasis who are candidates for systemic therapy. This review discusses the selection and acceptability of secukinumab in children with psoriasis.

5 February 2024 in Frontiers in Medicine
Verified
Journal Article
Open access
Michał NiedźwiedźMichał Niedźwiedź
Michał Niedźwiedź
JNJoanna Narbutt
Joanna Narbutt
ASAleksandra Siekierko
Aleksandra Siekierko
MSMałgorzata Skibińska
Małgorzata Skibińska
BKBartłomiej Kwiek
Bartłomiej Kwiek
ALAleksandra Lesiak
Aleksandra Lesiak
CARD14 (caspase activation and recruitment domain) mutations have been associated with psoriasis vulgaris, psoriatic arthritis, generalized and palmoplantar pustular psoriasis, pityriasis rubra pilaris, and atopic dermatitis. We present a pediatric patient with a novel CARD14: c.394A > T/− (Ile123Phe) mutation, diagnosed with CARD14-associated papulosquamous eruption (CAPE), who was successfully treated with biological treatment.

1 August 2021 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
JCJustyna Ceryn
Justyna Ceryn
Michał NiedźwiedźMichał Niedźwiedź
Michał Niedźwiedź
MSMałgorzata Skibińska
Małgorzata Skibińska
MCMagdalena Ciążyńska
Magdalena Ciążyńska
ALAleksandra Lesiak
Aleksandra Lesiak
JNJoanna Narbutt
Joanna Narbutt
There are limited clinical data on the impact of the SARS-CoV2 infection on patients with dermatological conditions treated with biologics. Dupilumab is a recombinant human IgG4 human monoclonal antibody that inhibits IL4 and IL13 signaling, and is used for moderate–severe atopic dermatitis treatment. We present three patients with atopic dermatitis (AD) treated with dupilumab who contracted COVID-19. In all patients, the infection had a mild course, and only in one, as documented by SCORAD, EASI, and DLQI scores, the condition of the skin deteriorated, and a prolonged positive PCR COVID-19 test was observed. The mechanism of dupilumab action and more evidence for IL13 importance in lung damage caused by SARS-CoV2 suggest a possible explanation for a mild–moderate course of the infection in treated AD patients. Based on current knowledge, there is evidence to continue dupilumab treatment in AD patients with mild–moderate COVID-19; however, careful assessment is needed for each patient.

1 January 2023 in Advances in Dermatology and Allergology
Verified
Journal Article
Closed access
Michał NiedźwiedźMichał Niedźwiedź
Michał Niedźwiedź
MSMałgorzata Skibińska
Małgorzata Skibińska
JNJoanna Narbutt
Joanna Narbutt
ALAleksandra Lesiak
Aleksandra Lesiak
Introduction: Off-label prescribing is defined as using medications outside conditions of the marketing authorisa-tion including their licensed indications, dosage, age and route. Atopic dermatitis (AD) is the most common chronic skin condition in children which can be related to a high level of off-label prescribing.Aim: To investigate the frequency of off-label prescribing and the medications involved in relation to indications and age in paediatric patients hospitalized for atopic dermatitis in a paediatric dermatology ward in 2019.Material and methods: One hundred and seventy-five consecutive discharge letters of patients were analysed regarding gender, age and medications used during hospital stay and prescribed on discharge. Each medication was checked against the licensed age and indications. Results: Altogether 564 medications were prescribed, including 289 topical and 275 systemic ones with 278 pre-scribed off-label (49.1%). Out of 289 topical medications, 113 (39.1%) were prescribed off-label regarding indica-tions and 34 (11.76%) regarding the age of the patients. In the systemic medications group, 96 (34.53%) were prescribed off-label as AD was not a registered indication and 35 (12.73%) as the age of the patients was outside the marketing authorization. The most frequent medications prescribed off-label were antihistamines, antibiotics and corticosteroids.Conclusions: Prescribing off-label in paediatric population is a common practice. Both topical and systemic medica-tions are frequently used in AD patients off-label, therefore doctors should be familiar with the pitfalls of prescribing beyond the licensed indications and age.